Head-to-head evidence
LY03003 vs SER-252 (PEOZ-apomorphine)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
LY03003
Developed by Luye Pharma Group
NCT04571164 · Phase 3 · completed
The trial randomized 294 participants to LY03003 or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in the clinical UPDRS parts II+III score over 24 weeks, but the primary comparison and safety findings are not available, preventing assessment of whether the endpoint was met.
SER-252 (PEOZ-apomorphine)
Developed by Serina Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07422675 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY03003's landscape · SER-252 (PEOZ-apomorphine)'s landscape